TY - JOUR
T1 - How Staying Negative Is Good for the (Adult) Brain
T2 - Maintaining Chloride Homeostasis and the GABA-Shift in Neurological Disorders
AU - Hui, Kelvin K.
AU - Chater, Thomas E.
AU - Goda, Yukiko
AU - Tanaka, Motomasa
N1 - Funding Information:
This work was supported by the RIKEN Center for Brain Science, Japan Agency for Medical Research and Development (AMED; JP21wm0525014h, JP15dm0207001, and 21gm1410009h to MT), Core-to-Core Program (JPJSCCA20220007 to YG) by Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Transformative Research Area (A) (21H05257 to MT) from Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan), and Japan Epilepsy Research Foundation (to MT).
Publisher Copyright:
Copyright © 2022 Hui, Chater, Goda and Tanaka.
PY - 2022/7/8
Y1 - 2022/7/8
N2 - Excitatory-inhibitory (E-I) imbalance has been shown to contribute to the pathogenesis of a wide range of neurodevelopmental disorders including autism spectrum disorders, epilepsy, and schizophrenia. GABA neurotransmission, the principal inhibitory signal in the mature brain, is critically coupled to proper regulation of chloride homeostasis. During brain maturation, changes in the transport of chloride ions across neuronal cell membranes act to gradually change the majority of GABA signaling from excitatory to inhibitory for neuronal activation, and dysregulation of this GABA-shift likely contributes to multiple neurodevelopmental abnormalities that are associated with circuit dysfunction. Whilst traditionally viewed as a phenomenon which occurs during brain development, recent evidence suggests that this GABA-shift may also be involved in neuropsychiatric disorders due to the “dematuration” of affected neurons. In this review, we will discuss the cell signaling and regulatory mechanisms underlying the GABA-shift phenomenon in the context of the latest findings in the field, in particular the role of chloride cotransporters NKCC1 and KCC2, and furthermore how these regulatory processes are altered in neurodevelopmental and neuropsychiatric disorders. We will also explore the interactions between GABAergic interneurons and other cell types in the developing brain that may influence the GABA-shift. Finally, with a greater understanding of how the GABA-shift is altered in pathological conditions, we will briefly outline recent progress on targeting NKCC1 and KCC2 as a therapeutic strategy against neurodevelopmental and neuropsychiatric disorders associated with improper chloride homeostasis and GABA-shift abnormalities.
AB - Excitatory-inhibitory (E-I) imbalance has been shown to contribute to the pathogenesis of a wide range of neurodevelopmental disorders including autism spectrum disorders, epilepsy, and schizophrenia. GABA neurotransmission, the principal inhibitory signal in the mature brain, is critically coupled to proper regulation of chloride homeostasis. During brain maturation, changes in the transport of chloride ions across neuronal cell membranes act to gradually change the majority of GABA signaling from excitatory to inhibitory for neuronal activation, and dysregulation of this GABA-shift likely contributes to multiple neurodevelopmental abnormalities that are associated with circuit dysfunction. Whilst traditionally viewed as a phenomenon which occurs during brain development, recent evidence suggests that this GABA-shift may also be involved in neuropsychiatric disorders due to the “dematuration” of affected neurons. In this review, we will discuss the cell signaling and regulatory mechanisms underlying the GABA-shift phenomenon in the context of the latest findings in the field, in particular the role of chloride cotransporters NKCC1 and KCC2, and furthermore how these regulatory processes are altered in neurodevelopmental and neuropsychiatric disorders. We will also explore the interactions between GABAergic interneurons and other cell types in the developing brain that may influence the GABA-shift. Finally, with a greater understanding of how the GABA-shift is altered in pathological conditions, we will briefly outline recent progress on targeting NKCC1 and KCC2 as a therapeutic strategy against neurodevelopmental and neuropsychiatric disorders associated with improper chloride homeostasis and GABA-shift abnormalities.
KW - GABA-shift
KW - Na-K-2Cl cotransporter-1 (NKCC1)
KW - chloride homeostasis
KW - neurodevelopmental disorders (NDD)
KW - neuropsychiatric disorders (NPD)
KW - potassium chloride cotransporter-2 (KCC2)
UR - http://www.scopus.com/inward/record.url?scp=85134660942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134660942&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2022.893111
DO - 10.3389/fnmol.2022.893111
M3 - Review article
AN - SCOPUS:85134660942
SN - 1662-5099
VL - 15
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 893111
ER -